We are live on
!
Find out more
First Manhattan Portfolio holdings
AUM
$36.1B
1-Year Est. Return
11.5%
This Fund
S&P 500
This Quarter
Est. Return
+4.31%
1 Year Est. Return
+11.5%
3 Year Est. Return
+74.65%
5 Year Est. Return
+103.66%
10 Year Est. Return
+354.63%
AUM
$16.4B
AUM Growth
+$49.9M
(+0.3%)
Cap. Flow
-$355M
Cap. Flow
% of AUM
-2.16%
Top 10 Holdings %
Top 10 Hldgs %
43.8%
Holding
1,532
New
77
Increased
144
Reduced
521
Closed
96
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coty
COTY
|
+$139M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$38M |
| 3 |
GCP
GCP Applied Technologies Inc.
GCP
|
+$34.7M |
| 4 |
Sonida Senior Living
SNDA
|
+$25.5M |
| 5 |
Theravance Biopharma
TBPH
|
+$24.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$68M |
| 2 |
ConocoPhillips
COP
|
+$44.3M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$35.7M |
| 4 |
Zimmer Biomet
ZBH
|
+$33.7M |
| 5 |
Berkshire Hathaway Class A
BRK.A
|
+$26.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 37.47% |
| 2 | Healthcare | 12.64% |
| 3 | Industrials | 9.32% |
| 4 | Technology | 8.7% |
| 5 | Consumer Staples | 6.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Berkshire Hathaway Class A
BRK.A
$1.06T
| $3.58B | 21.79% |
14,679
-115
| -0.8% | -$26.5M |
|
2
Brookfield
BN
$101B
| $558M | 3.39% |
47,355,993
-1,315,409
| -3% | -$16M |
|
3
Microsoft
MSFT
$2.83T
| $501M | 3.05% |
8,066,837
-26,134
| -0.3% | -$1.57M |
|
|
4
Berkshire Hathaway Class B
BRK.B
$1.06T
| $452M | 2.75% |
2,774,579
-15,865
| -0.6% | -$2.44M |
|
5
Apple
AAPL
$4.72T
| $433M | 2.63% |
14,962,404
-152,844
| -1% | -$4.33M |
|
6
Johnson & Johnson
JNJ
$624B
| $298M | 1.81% |
2,588,309
-31,556
| -1% | -$3.65M |
|
7
AB InBev
BUD
$155B
| $256M | 1.56% |
2,426,205
-62,109
| -2% | -$6.96M |
|
8
Honeywell
HON
$78B
| $242M | 1.47% |
2,313,468
+2,866
| +0.1% | +$291K |
|
9
Wells Fargo
WFC
$261B
| $237M | 1.44% |
4,306,341
-204,382
| -5% | -$10.3M |
|
|
10
Zimmer Biomet
ZBH
$17.3B
| $233M | 1.42% |
2,327,493
-314,838
| -12% | -$33.7M |
|
11
Danaher
DHR
$135B
| $227M | 1.38% |
3,283,227
-24,926
| -0.8% | -$1.73M |
|
12
Comcast
CMCSA
$78.3B
| $218M | 1.32% |
6,306,154
-87,924
| -1% | -$2.94M |
|
13
CVS Health
CVS
$136B
| $209M | 1.27% |
2,652,359
-153,095
| -5% | -$12.4M |
|
14
Aramark
ARMK
$15B
| $193M | 1.18% |
7,495,563
-208,810
| -3% | -$5.46M |
|
15
Gilead Sciences
GILD
$162B
| $192M | 1.17% |
2,683,990
+79,101
| +3% | +$5.88M |
|
16
Pfizer
PFE
$143B
| $168M | 1.02% |
5,450,311
+616,271
| +13% | +$18.8M |
|
17
Philip Morris
PM
$298B
| $155M | 0.94% |
1,697,697
-26,507
| -2% | -$2.46M |
|
18
American International
AIG
$41.4B
| $138M | 0.84% |
2,115,141
-265,859
| -11% | -$16.7M |
|
19
Newell Brands
NWL
$2.14B
| $137M | 0.83% |
3,059,015
+140,390
| +5% | +$6.79M |
|
20
3M
MMM
$87.5B
| $132M | 0.8% |
883,580
-15,374
| -2% | -$2.22M |
|
21
IBM
IBM
$194B
| $129M | 0.79% |
815,069
-29,782
| -4% | -$4.54M |
|
22
Accenture
ACN
$84.9B
| $128M | 0.78% |
1,092,329
-49,587
| -4% | -$5.89M |
|
23
Oracle
ORCL
$346B
| $126M | 0.76% |
3,266,517
+220,401
| +7% | +$8.62M |
|
|
24
Coty
COTY
$2.29B
| $123M | 0.75% |
+6,723,666
| New | +$139M |
|
25
GE Aerospace
GE
$362B
| $121M | 0.74% |
800,415
-12,254
| -2% | -$1.78M |
|
Similar funds
SAM
First Manhattan's Q4 2016 Portfolio in Review
As of Q4 2016, First Manhattan held 1,532 positions worth $16.4B, up 0.3% from $16.4B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
First Manhattan's Q4 2016 filing shows 77 new, 144 increased, 521 reduced and 96 closed positions. Its largest new stake was Coty: 6,723,666 shares worth $123M. The largest sale was Allergan plc, an estimated $68M.
By sector, the portfolio is most concentrated in Financials at 37% of assets, up from 35% a quarter earlier, followed by Healthcare and Industrials.
- First Manhattan's largest Q4 2016 buy was Coty: 6,723,666 shares worth $123M.
- First Manhattan added most to Teva Pharmaceuticals in Q4 2016, an estimated $38M increase.
- First Manhattan's biggest Q4 2016 reduction was Allergan plc, cutting an estimated $68M.
- First Manhattan fully exited Starz - Series A in Q4 2016, selling an estimated $2.9M.
- First Manhattan's ten largest holdings make up 44% of its $16.4B portfolio in Q4 2016.
- First Manhattan opened 77 new positions and closed 96 in Q4 2016.
- First Manhattan's portfolio value rose 0.3% quarter-over-quarter to $16.4B.
Based on First Manhattan's 13F filing for Q4 2016, filed 25 Jan 2017.